Epileptic Disorders

Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Retrieved on: 
월요일, 12월 5, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Longboard, Epileptic Disorders, Cmax, Security (finance), Disagreement, Chemistry, G protein-coupled receptor, Judgement, Cohort, Food, Observation, Female, Tmax, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Central nervous system, GABA, Graduate School of Asia-Pacific Studies, Plasma, Patient, Quantitative electroencephalography, GPCR, Lennox–Gastaut syndrome, LGS, Research, CDD, CSF, License, Medication, Dees, Government, Day, TID, CDKL5, COVID-19, TSC, Trial of the century, Dravet syndrome, Clinical trial, EEG, Safety, Pharmacokinetics, Marketing, AES, PD, Seizure, CNS, Male, Acquisition, Pharmaceutical industry, Palladium, Pfizer

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline results from a Phase 1 clinical study evaluating the central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (PD) of LP352, an oral, centrally acting 5-HT2C superagonist, in healthy volunteers.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline results from a Phase 1 clinical study evaluating the central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (PD) of LP352, an oral, centrally acting 5-HT2C superagonist, in healthy volunteers.
  • The primary objectives of this open-label, Phase 1 study are to assess the CNS PK and PD of orally administered LP352 in healthy adult male and female participants (n=10 in each Cohort).
  • At steady state, LP352 12 mg TID mean concentrations exceeded the Ki value for 5-HT2C activity throughout the dosing interval.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

PANTHERx® Rare Announces Partnership with Biocodex for the Distribution of DIACOMIT® (stiripentol) for the Treatment of Seizures Associated with Dravet Syndrome in Patients 2 Years of Age and Older Taking Clobazam

Retrieved on: 
월요일, 6월 27, 2022
Diagnosis, ACHC, FDA, Death, Science, Patient, Accreditation Commission for Health Care, Epilepsy, Research, NABP, Population, Degenerative disease, Multimedia, Disease, SCN1A, SMEI, Mortality, United, Demographics of the United States, Seizure, Partnership, Incidence, Quality of life, Pediatrics, National Association, Pharmacy, Medicine, NASP, Epileptic Disorders, SUDEP, Specialty pharmacy, URAC, Mutation, Diabetes, Fever, Pharmaceutical industry, Dravet syndrome

DIACOMIT is a new molecular entity approved by the FDA in 2018 for the adjunctive treatment of seizures associated with Dravet syndrome in those 2 years of age and older taking clobazam.

Key Points: 
  • DIACOMIT is a new molecular entity approved by the FDA in 2018 for the adjunctive treatment of seizures associated with Dravet syndrome in those 2 years of age and older taking clobazam.
  • Dravet syndrome is a lifelong disorder that can be associated with severe complications and decreased quality of life.
  • The seizures associated with Dravet syndrome are often considered difficult to treat requiring patients to try multiple antiseizure medications.
  • Our partnership will allow the Dravet syndrome community renewed hope for improved health outcomes," said Rob Snyder, President of PANTHERx.

Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer

Retrieved on: 
수요일, 6월 1, 2022
Life, International Family Planning and Development, Chemistry, Graduate School of Asia-Pacific Studies, Lennox–Gastaut syndrome, TSC, Seizure, Epilepsy, Research, Dravet Syndrome Foundation, Marketing, Epileptic Disorders, GABA, Conference, Safety, CDKL5, Central nervous system, Longboard, CDD, G protein-coupled receptor, Forward-looking statement, Syndrome, GPCR, Dravet syndrome, Government, Security (finance), U.S. Securities and Exchange Commission, LGS, GLOBE, Patient, Disagreement, DSF, Private Securities Litigation Reform Act, Coronavirus, Acquisition, COVID-19, Lists of diseases, Dees, Judgement, SEC, SAN, Myoclonus, CNS, Epileptic spasms, CB2, Pharmaceutical industry

"We are pleased to be included in these key epilepsy conferences this summer.

Key Points: 
  • "We are pleased to be included in these key epilepsy conferences this summer.
  • LP352 is designed to modulate GABA and, as a result, suppress the central hyperexcitability that is characteristic of seizures.
  • Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Worldwide Kainic Acid Industry to 2027 - Featuring Abcam, Alfa Chemistry and Cayman Chemical Among Others - ResearchAndMarkets.com

Retrieved on: 
목요일, 4월 28, 2022
Health, Pharmaceutical, WHO, World Health Organization, Temporal lobe epilepsy, Kainic acid, Incidence, Prevalence, Epilepsy, World, Government, TLE, Epileptic Disorders, Pharmaceutical industry, Marketing

This rising prevalence of epilepsy disorder around the globe is expected to drive the global kainic acid market.

Key Points: 
  • This rising prevalence of epilepsy disorder around the globe is expected to drive the global kainic acid market.
  • The global kainic acid market is segmented based on type and application.
  • Based on type, the kainic acid market is segmented into high purity (above 99%), low purity (below 97%), purity (above 97% and below 99%) kainic acid.
  • Analysis of regional regulations and other government policies impacting the global kainic acid market.

Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting

Retrieved on: 
금요일, 4월 1, 2022
Private Securities Litigation Reform Act, Dees, Lists of diseases, Dose, CDD, GABA, Seizure, GPCR, American Academy of Neurology, Pharmacokinetics, Central nervous system, Judgement, CNS, Research, SEC, Epileptic Disorders, Program, DEE, Dravet syndrome, U.S. Securities and Exchange Commission, Prolactin, Security (finance), LGS, Lennox–Gastaut syndrome, Annual general meeting, TSC, CB2, GLOBE, American Academy, Chemistry, AAN, SAN, G protein-coupled receptor, Patient, CDKL5, Graduate School of Asia-Pacific Studies, Pharmaceutical industry

"At AAN, we are presenting data highlighting favorable safety, tolerability, pharmacokinetics and pharmacodynamics that were observed in our Phase 1 trial in healthy volunteers.

Key Points: 
  • "At AAN, we are presenting data highlighting favorable safety, tolerability, pharmacokinetics and pharmacodynamics that were observed in our Phase 1 trial in healthy volunteers.
  • LP352 is designed to modulate GABA inhibition and, as a result, suppress the central hyperexcitability that is characteristic of seizures.
  • LP352 is currently being evaluated in the Phase 1b/2a PACIFIC Study in approximately 50 participants with a range of DEEs.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions

Retrieved on: 
수요일, 12월 8, 2021
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Monash University, Anxiety, Twitter, Environment, Synthetic, Company, Research, SEC, LSE, Technology, Therapy, Annual general meeting, University of Melbourne, Platform supply vessel, PRTC, Immune system, Monash Institute of Medical Research, Safety, Allopregnanolone, Control, Private Securities Litigation Reform Act, GABAA, BIG, Cancer, Brain, Axis, Liver, Journal, Lymphatic system, Fat, PK, Epilepsy, American College, Depression, Epileptic Disorders, Sleep, Multimedia, Trial of the century, Pharmacy, FDA, PureTech Health, Essential tremor, Biology, Degenerative disease, U.S. FDA, Annual report, Prodrug, Pharmaceutical industry

Synthetic oral analogs of allopregnanolone have had variable clinical success, and comparable activity with natural allopregnanolone remains to be established.

Key Points: 
  • Synthetic oral analogs of allopregnanolone have had variable clinical success, and comparable activity with natural allopregnanolone remains to be established.
  • The data presented at ACNP showed that systemic exposure of natural allopregnanolone was achieved after oral administration of LYT-300 in multiple preclinical models of increasing complexity.
  • LYT-300 is a clinical therapeutic candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions.
  • Allopregnanolone is a positive allosteric modulator of -aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions.

PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions

Retrieved on: 
화요일, 12월 7, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Sleep, Monash University, Anxiety, Twitter, Environment, Synthetic, Company, Lists of diseases, Research, SEC, LSE, Technology, Therapy, Pharmacokinetics, University of Melbourne, Platform supply vessel, PRTC, Immune system, Monash Institute of Medical Research, Allopregnanolone, Safety, Control, GABAA, BIG, Cancer, Brain, Axis, Private Securities Litigation Reform Act, Liver, Food, Journal, Lymphatic system, Fat, PK, Epilepsy, Depression, Epileptic Disorders, Multimedia, Trial of the century, Pharmacy, FDA, PureTech Health, Essential tremor, Biology, Degenerative disease, U.S. FDA, Annual report, Prodrug, Pharmaceutical industry

LYT-300 is designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need.

Key Points: 
  • LYT-300 is designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need.
  • Allopregnanolone is a powerful, natural regulator of mood disorders and other neurological conditions, but its therapeutic development has been limited by its poor oral bioavailability.
  • LYT-300 is a clinical therapeutic candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions.
  • Allopregnanolone is a positive allosteric modulator of -aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions.

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial

Retrieved on: 
수요일, 9월 8, 2021

Longboard plans to advance LP352 into a Phase 1b/2a efficacy trial in adult participants with DEEs in the first quarter of 2022 in study sites across the United States.

Key Points: 
  • Longboard plans to advance LP352 into a Phase 1b/2a efficacy trial in adult participants with DEEs in the first quarter of 2022 in study sites across the United States.
  • The LP352 Phase 1 trial (N=83) was a first-in-human, randomized, placebo-controlled, double-blind, four-part trial including single ascending dose (SAD) and MAD assessments in healthy volunteers.
  • The primary objectives of the trial were to evaluate safety, tolerability, PK & PD of LP352.
  • In the MAD portion (N=43) of the trial, five doses including the maximum planned dose were evaluated.